Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Sept 14: After announcing Tuesday that its CRF1 antagonist, crinecerfont, met the primary efficacy endpoint in the Phase III CAHtalyst Adult Study for classic congenital adrenal hyperplasia, Neurocrine Biosciences reported good news on the neuro front
Addressing these gaps is essential for translating basic mechanistic insight into clinically meaningful strategies
Comment: A few commenters recommended CMS keep the requirement to encode the estimated allowed amount in the MRF instead of replacing it with the median allowed amount and adding the 10th and 90th percentile allowed amounts, indicating they believe that given the volume and complexity of the MRFs, the average would provide a more accurate estimate of what a hospital has historically received for that item or service
The retrospective cohort study, GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer, published in the August 2025 edition of Oncology , 3 was based on data from 116 patients with a breast cancer diagnosis prescribed GLP-1 RAs at the Memorial Sloan Kettering Cancer Center, from 2015 to 2023
But what exactly are they, how do they work, and which one is right for you
Effects of Mindful Eating in Patients with Obesity and Binge Eating Disorder
